Update on the emerging role of telavancin in hospital-acquired infections

Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nnedu, Obinna N, Pankey, George A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403509/
https://www.ncbi.nlm.nih.gov/pubmed/25926737
http://dx.doi.org/10.2147/TCRM.S57376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403509/
https://www.ncbi.nlm.nih.gov/pubmed/25926737
http://dx.doi.org/10.2147/TCRM.S57376

Ejemplares similares